Pegaptanib sodium for macular edema due to retinal-vein occlusion among patients intolerant to intravitreal triamcinolone acetonide

Ellen N Yu; Pik Sha Chan; Amadeo AS Veloso; Harvey S Uy

Return

Pegaptanib sodium for macular edema due to retinal-vein occlusion among patients intolerant to intravitreal triamcinolone acetonide

Author: Ellen N. Yu ¹ ; Pik Sha Chan ¹ ; Amadeo A.S. Veloso ¹ ; Harvey S Uy ^{1
,

2}
Author Information

1. Asian Eye Institute Makati, Philippines
2. Department of Ophthalmology and Visual Sciences Sentro Oftalmologico Jose Rizal University of the Philippines-Philippine General Hospital Manila, Philippines
Publication Type:Case Reports
Keywords: Retinal-vein occlusion; Intravitreal triamcinolone acetonide; Anti-vascular endothelial growth factor (anti-VEGF
MeSH: Macular Edema
From: Philippine Journal of Ophthalmology 2010;35(2):79-81
CountryPhilippines
Language:English
Abstract: Objective:To report the efficacy and safety of intravitreal pegaptanib sodium (IVP) on macular edema (ME) due to branch retinal-vein occlusion (BRVO) among patients intolerant to intravitreal triamcinolone acetonide (IVTA).
Methods:Four eyes with ME due to BRVO were included in this interventional case series. The main outcome measures were best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), and adverse effects.
Results:There was a significant decrease in mean CMT from 524.50 ± 141.12 to 293.75 ± 130.75 microns (p = 0.009) after IVP injection. BCVA improved in all 4 eyes after IVP. Mean IOP after IVP was 13.60 ± 3.21. No ocular or systemic complications were observed.
Conclusion:IVP appears to be safe and effective in decreasing retinal thickness and improving VA in eyes with ME due to BRVO. IVP is a potential treatment for eyes that are intolerant to IVTA.
Full text:PJO 118.pdf